Medicago’s plant-based vaccine trial shows 75.3% efficacy against Delta variant
According to Reuters, “Canadian drug developer Medicago’s plant-based COVID-19 vaccine candidate, enhanced by GlaxoSmithKline’s (GSK.L) booster, was 75.3% effective against the Delta variant of the virus in a late stage study.” … “Medicago will imminently seek regulatory approval for the world’s first plant-based COVID-19 vaccine from Health Canada as part of its rolling submission.”
For article, see: https://www.reuters.com/business/healthcare-pharmaceuticals/medicagos-plant-based-vaccine-trial-shows-753-efficacy-against-delta-variant-2021-12-07/
This vaccine information may also be of interest:
How plant-based vaccines are developed?
The contents of this posting, website, and our other publications, including The Vegetarian Journal, are not intended to provide personal medical advice. Medical advice should be obtained from a qualified health professional. We often depend on product and ingredient information from company statements. It is impossible to be 100% sure about a statement, info can change, people have different views, and mistakes can be made. Please use your best judgment about whether a product is suitable for you. To be sure, do further research or confirmation on your own.
